首页> 美国卫生研究院文献>Bioinformatics >Drug repositioning based on bounded nuclear norm regularization
【2h】

Drug repositioning based on bounded nuclear norm regularization

机译:基于有界核规范正则化的药物重新定位

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MotivationComputational drug repositioning is a cost-effective strategy to identify novel indications for existing drugs. Drug repositioning is often modeled as a recommendation system problem. Taking advantage of the known drug–disease associations, the objective of the recommendation system is to identify new treatments by filling out the unknown entries in the drug–disease association matrix, which is known as matrix completion. Underpinned by the fact that common molecular pathways contribute to many different diseases, the recommendation system assumes that the underlying latent factors determining drug–disease associations are highly correlated. In other words, the drug–disease matrix to be completed is low-rank. Accordingly, matrix completion algorithms efficiently constructing low-rank drug–disease matrix approximations consistent with known associations can be of immense help in discovering the novel drug–disease associations.
机译:动机计算药物重新定位是一种识别现有药物新适应症的经济有效策略。药物重新定位通常被建模为推荐系统问题。利用已知的药物-疾病关联,推荐系统的目的是通过填写药物-疾病关联矩阵中的未知条目(称为矩阵完成)来识别新疗法。在常见分子途径导致许多不同疾病的事实的支持下,推荐系统假设确定药物-疾病关联的潜在因素高度相关。换句话说,要完成的药物-疾病矩阵是低等级的。因此,有效地构建与已知关联相一致的低阶药物-疾病矩阵近似的矩阵完成算法,对于发现新型药物-疾病关联具有巨大帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号